These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37449085)

  • 1. Durable remission in a patient with
    Neil AJ; Muto MG; Kolin DL; Konstantinopoulos PA
    Gynecol Oncol Rep; 2023 Aug; 48():101237. PubMed ID: 37449085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
    McAlpine JN; Wiegand KC; Vang R; Ronnett BM; Adamiak A; Köbel M; Kalloger SE; Swenerton KD; Huntsman DG; Gilks CB; Miller DM
    BMC Cancer; 2009 Dec; 9():433. PubMed ID: 20003286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucinous epithelial ovarian carcinoma.
    Perren TJ
    Ann Oncol; 2016 Apr; 27 Suppl 1():i53-i57. PubMed ID: 27141073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
    Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers S; Secord AA; Havrilesky L; O'Malley DM; Backes FJ; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi K; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
    Clin Cancer Res; 2020 Aug; 26(15):3928-3935. PubMed ID: 32601075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in
    Fang X; Mou H; Ying X; Hou X; Wang L; Wu Y; Yan N; Guo L; Liao Q
    Front Oncol; 2022; 12():1024677. PubMed ID: 36620566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
    Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers SK; Secord AA; Havrilesky L; O'Malley DM; Backes F; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi KS; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
    J Clin Oncol; 2018 Jul; 36(20):2044-2051. PubMed ID: 29584549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
    Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
    Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertility-Sparing Surgery and Adjuvant Chemotherapy with Trastuzumab Result in Complete Remission in a Young Woman with Rare Primary Mucinous Ovarian Cancer due to ERBB2 Co-amplification with CDK12 and Chromosome 11q13.3 Amplicon: A Case Report and Literature Review.
    Gao L; Huang T; Zhong L; Peng L; Huang Z; Lu Y
    Reprod Sci; 2024 Jun; 31(6):1626-1631. PubMed ID: 38216775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
    Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
    Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
    Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
    Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
    Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent malignant ovarian adenocarcinoma with central nervous system metastasis successfully treated with paclitaxel, carboplatin, capecitabine, and gemcitabine.
    Shahrokh S; Salmanian S; Shahin M
    Proc (Bayl Univ Med Cent); 2023; 36(2):234-236. PubMed ID: 36876271
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.